The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antibodies Against Oxidized Phospholipids Protect Against Osteoporosis

Antibodies Against Oxidized Phospholipids Protect Against Osteoporosis

October 18, 2018 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Kateryna Kon / shutterstock.com

Kateryna Kon / shutterstock.com

It has long been known that hyperlipidemia adversely affects bone, but the exact pathologic mechanism(s) underlying hyperlipidemia-induced bone loss has not been fully understood. Until now.

You Might Also Like
  • SIRT1: A Therapeutic Target for Osteoporosis?
  • Sensory Nerves May Be Key for Osteoporosis
  • Oxidized Mitochondrial DNA May Contribute to Inflammation in SLE
Explore This Issue
October 2018
Also By This Author
  • Chronic Pain Research Probes Neurologic Pain Pathways, Biomarkers

Pathogenesis of Osteoporosis

New research by Ambrogini and colleagues shows that oxidation-specific epitopes derived from lipid peroxidation contribute to the pathogenesis of osteoporosis.1 Importantly, the research shows that innate immune antibodies against these epitopes can offer a protective effect against the disease—at least in mice.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“There are antibodies against oxidized phospholipids that are protective against osteoporosis,” says lead author of the study, Elena Ambrogini, MD, PhD, assistant professor, Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, University of Arkansas for Medical Sciences and Central Arkansas Veterans HealthCare System, directed by Stavros C. Manolagas, MD, PhD, in Little Rock, Ark. “We have shown in mice that if you overexpress these antibodies, the mice have more bone.”

“This is the first proof-of-principle that oxidation-specific epitopes are involved in bone metabolism,” she says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pathogenesis of Atherosclerosis

Dr. Ambrogini

Dr. Ambrogini

The study by Ambrogini et al. comes on the heels of another recently published study by Que et al. that demonstrates for the first time what has long been recognized without demonstrable proof—oxidized phospholipids contribute to the pathogenesis of atherosclerosis.2 Although it has long been suspected that oxidized phospholipids and oxidized low-density lipoprotein are involved in the pathogenesis of atherosclerosis, the study by Que et al. was the first to demonstrate this in vivo in murine models, according to senior author of the study, Joseph Witztum, MD, professor of medicine, Division of Endocrinology and Metabolism, University of California, San Diego.

Dr. Witztum, who is also a co-investigator in the osteoporosis study, emphasizes the implication of these results for humans. “We believe this is relevant to humans [because] oxidized phospholipids can be demonstrated to be abundant in almost all atherosclerotic lesions in humans,” he says.

As for osteoporosis, Dr. Witztum says further research is needed to determine the relevance to humans of the finding that oxidized phospholipids contribute to this disease as well.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

If such research pans out, the hope is that one day a new therapeutic agent will be able to simultaneously target both osteoporosis and atherosclerosis.

‘This is the first proof-of-principle that oxidation-specific epitopes are involved in bone metabolism.’ —Dr. Ambrogini

Common Pathogenesis/Common Treatment

Epidemiological data have shown that osteoporosis, atherosclerosis and a high fat diet are linked. The new research demonstrates for the first time, in vivo in murine models, that oxidation-specific epitopes are an important common pathogenic factor that may underlie these links. In specific, the research shows that oxidized phospholipids impair the function of osteoblasts, the cells that build new bone.

For atherosclerosis, the potential involvement of these oxidation-specific epitopes has long been recognized, says Dr. Witztum. What is truly novel, he emphasizes, is demonstrating this same pathogenic mechanism underlies osteoporosis.

Ambrogini et al. discovered the common mechanisms underlying osteoporosis by examining the role of oxidation-specific epitopes in bone homeostasis in murine models. Using mice overexpressing antibodies that block the effects of oxidation-specific epitopes, the investigators found they could attenuate the high-fat-diet-induced loss of bone mass in these mice.

Importantly, the study also found that one of those antibodies increases bone mass not only in mice fed a high-fat diet, but also in mice fed a normal diet.

Dr. Witztum

Dr. Witztum

According to Dr. Witztum, this strongly implies “that even under physiological conditions, oxidized phospholipids impair bone anabolism.” As such, he emphasized the need to better understand where the oxidation-specific epitopes are coming from. “This remains to be determined, but we have shown that as cells undergo apoptosis there is generation of oxidized phospholipids and that oxidized phospholipids are frequently present on vesicles released from cells, so in a period of rapid growth and bone turnover early in life one might speculate that this could be a source,” he says.

Given the attenuation of bone loss in the mice overexpressing the antibodies that block the oxidation-specific epitopes, the study does suggest these epitopes as a new potential therapeutic target for osteoporosis.

“It is known that these antibodies are already protective against cardiovascular disease in humans,” says Dr. Ambrogini. “Now we have to look at whether this is true for osteoporosis.”

Emphasizing that the study by Ambrogini and colleagues showed antibodies targeting oxidized phospholipids ameliorated their adverse effects on bone, Dr. Witztum says further study is needed to fully understand the pathogenetic mechanisms of these oxidation-specific epitopes. “Importantly, it remains to be determined if treatment to neutralize oxidized phospholipids after the diseases have been established will lead to prevention of advancement or even regression,” he says.


Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis.

References

  1. Ambrogini E, Que X, Wang S, et al. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018 Jun 6;9(1):2193.
  2. Que X, Hung MY, Yeang C, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018 Jun; 558(7709):301–306.

Pages: 1 2 | Multi-Page

Filed Under: Conditions Tagged With: atherosclerosis, bone loss, OsteoporosisIssue: October 2018

You Might Also Like:
  • SIRT1: A Therapeutic Target for Osteoporosis?
  • Sensory Nerves May Be Key for Osteoporosis
  • Oxidized Mitochondrial DNA May Contribute to Inflammation in SLE
  • Teriparatide to Denosumab Switch Helpful in Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)